Related Experiment Video
Updated: Feb 22, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Enhancing tumor specific immune responses by transcutaneous vaccination
Hanadi Saliba1,2, Béatrice Heurtault1, Hasnaa Bouharoun-Tayoun2
1a Laboratory of Design and Application of Bioactive Molecules , University of Strasbourg , Illkirch Cedex , France.
Introduction:
Our understanding of the involvement of the immune system in cancer control has increased over recent years. However, the development of cancer vaccines intended to reverse tumor-induced immune tolerance remains slow as most current vaccine candidates exhibit limited clinical efficacy. The skin is particularly rich with multiple subsets of dendritic cells (DCs) that are involved to varying degrees in the induction of robust immune responses. Transcutaneous administration of cancer vaccines may therefore harness the immune potential of these DCs, however, this approach is hampered by the impermeability of the stratum corneum. Innovative vaccine formulations including various nanoparticles, such as liposomes, are therefore needed to properly deliver cancer vaccine components to skin DCs. Areas covered: The recent insights into skin DC subsets and their functional specialization, the potential of nanoparticle-based vaccines in transcutaneous cancer vaccination and, finally, the most relevant clinical trial advances in liposomal and in cutaneous cancer vaccines will be discussed. Expert commentary: To define the optimal conditions for mounting protective skin DC-induced anti-tumor immune responses, investigation of the cellular and molecular interplay that controls tumor progression should be pursued in parallel with clinical development. The resulting knowledge will then be translated into improved cancer vaccines that better target the most appropriate immune players.
Insights
Developing effective cancer vaccines faces challenges due to limited clinical efficacy. Nanoparticle-based vaccines delivered transcutaneously show promise by targeting skin dendritic cells (DCs) to overcome immune tolerance.
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Cancer vaccine development is hindered by tumor-induced immune tolerance, leading to low clinical efficacy.
- The skin contains diverse dendritic cell (DC) subsets crucial for initiating potent immune responses.
- Transcutaneous vaccine delivery is limited by the stratum corneum's impermeability.
Purpose of the Study:
- To review recent advancements in understanding skin dendritic cell subsets and their roles in immunity.
- To explore the potential of nanoparticle-based formulations for transcutaneous cancer vaccination.
- To discuss clinical trial progress in liposomal and cutaneous cancer vaccines.
Main Methods:
- Literature review of recent insights into skin DC subsets and their functional specialization.
- Analysis of nanoparticle-based vaccine strategies for transcutaneous delivery.
- Evaluation of clinical trial data for liposomal and cutaneous cancer vaccines.
Main Results:
- Skin dendritic cells offer a promising target for cancer vaccines.
- Nanoparticles, particularly liposomes, can enhance transcutaneous delivery of vaccine components to skin DCs.
- Clinical trials are exploring novel formulations for improved cancer vaccine efficacy.
Conclusions:
- Overcoming skin barrier challenges is key for effective transcutaneous cancer vaccination.
- Targeting specific skin dendritic cell subsets with advanced formulations like nanoparticles can enhance anti-tumor immunity.
- Further research into the immune-tumor interplay is essential for developing next-generation cancer vaccines.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:51Vaccinations
01:40Cell-mediated Immune Responses